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Abstract
In eukaryotic cells, the transcription of genes is accurately
orchestrated both spatially and temporally by the C-terminal
domain of RNA polymerase II (CTD). The CTD provides a
dynamic platform to recruit different regulators of the
transcription apparatus. Different posttranslational modifi-
cations are precisely applied to specific sites of the CTD to
coordinate transcription process. Regulators of the RNA
polymerase II must identify specific sites in the CTD for
cellular survival, metabolism, and development. Even though
the CTD is disordered in the eukaryotic RNA polymerase II
crystal structures due to its intrinsic flexibility, recent
advances in the complex structural analysis of the CTD
with its binding partners provide essential clues for under-
standing how selectivity is achieved for individual site
recognition. The recent discoveries of the interactions
between the CTD and histone modification enzymes disclose
an important role of the CTD in epigenetic control of the
eukaryotic geneexpression. Theintersection of the CTD code
with the histone code discloses an intriguing yet complicated
network for eukaryotic transcriptional regulation.
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B
iological systems have long served as a source of
inspiration for engineering, resulting in numerous
inventions based on biomimetics. During the last
few decades, as electronics-based information technology
has matured and flourished, our understanding of the
biological system has also proceeded to the molecular
and informational level. Such understanding has enabled
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tasks, such as the production of proteins and metabolites
for medical and industrial purposes. Recent development
of systems and synthetic biology promises the develop-
ment of cells with even more complex artificial functions
that will require the collaboration of a large number of
genes. With a similar philosophy, information-based
molecular programming has also been established as a
new path for nanotechnology. Central to all these new
technologies, cellular or acellular, is the encoding and
decoding of information at the molecular level, particu-
larly using DNA as the information carrier. Therefore,
from both a scientific and engineering point of view, it is
important to understand how biological systems read
information from DNA.
In biology, the major interpretation of this genetic
information is through transcription regulation where
eukaryotic RNA polymerase II plays the central role of
transcribing the genetic information to the expressed
protein. A special domain of RNA polymerase II func-
tions as master controller for the transcription process by
providing the template to recruit regulatory proteins to
nascent mRNA (1). The conformational states of the
CTD of RNA polymerase II, termed the CTD code,
represent a critical regulatory check point for transcrip-
tion (2 4). The CTD, found only in eukaryotes, consists of
26 52 tandem heptapeptide repeats generally with the
consensus sequence, Tyr1Ser2Pro3Thr4Ser5Pro6Ser7 (1).
Alterations of the sequence or the copy number of the
heptapeptide may lead to distinguishable phenotypes or
cell death (5, 6). The CTD can spatially and temporally
recruit different regulatory and processing factors to the
transcriptional machinery, reviewed in Corden (1) (Fig. 1)
but the domain is disordered in X-ray crystal structures.
The CTD phosphorylation is a major mechanism by
which cells regulate gene expression, with serines at
position 2 and 5 as major phosphorylation sites (7).
Recently, Ser7 was also found to be phosphorylated in vivo
although its function is still elusive (5). A secondary
mechanism for CTD regulation is prolyl-isomerization
of the two prolines in the CTD heptapeptide sequence
(Fig. 2). By adjusting the cis trans conformation of a
proline adjacent to a phosphorylated serine, interaction
of the CTD and binding partners it recruits can be
modulated.
Coordinately regulated phosphorylation and depho-
sphorylation of the CTD plays an essential role not only
in the recruitment and assembly of transcription com-
plexes but also in temporal control of transcription and
mRNA processing, reviewed in Refs (8, 9). Evidence
points to the phosphorylation state of Ser2 and Ser5 as
the trigger for transcriptional process modulation. Ser5
phosphorylation is required for assembly of the preinitia-
tion complex (PIC) and facilitates mRNA capping via
recruitment of capping enzymes (10, 11). During the
transition when the transcription complex moves
away from the initiation site, Ser5 gradually becomes
dephosphorylated, whereas Ser2 is phosphorylated. Ser2
phosphorylation is the predominant CTD pattern on
both elongating and terminating RNA Polymerase II,
which ensures efficient 3?-RNA processing by triggering
recruitment of 3?-RNA processing machinery (8). At the
end of transcription, CTDs are free of phosphate groups;
non-phosphorylated CTDs are required for RNA poly-
merase II to recycle and bind a promoter for the next
cycle of transcription (8). Little is known about the
timing of Ser7 phosphorylation and how it affects the
transcription but it appears to be an essential event
specific for snRNA expression (12).
One central question for CTD-directed transcription
regulation is how high resolution recognition of different
Fig. 1. Model of the CTD of RNA polymerase II. The RNA
polymerase II is coloredwith purple. Different shapes bound
to the CTD indicate various proteins that are recruited by
the CTD. Magenta circles labeled with ‘P’ indicate phos-
phorylation on the CTD. One repeat in the black circle is
zoomed in to show its primary sequence ‘YSPTSPS’. The
Ser2 and Ser5 (colored with magenta) are always phosphory-
lated in each round of transcription, and Tyr1 and Ser7
(colored with yellow) are also detected as phosphorylation
sites in vivo.
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Ser2 and Ser5 are highly similar, so it is puzzling how the
transcription regulation is managed with such precision
in location and timing. The most direct way to visualize
and identify molecular elements in binding specificity is
X-ray crystallography. A careful examination of the
primary sequence of the CTD reveals the possibility
that the CTD might have little secondary structure until
its association with binding partners. In this review, we
will discuss our current understanding of the CTD
structure and how the CTD is recognized by its binding
partners (Table 1).
Pin1 and the C-terminal domain (CTD)
The first glimpse of the CTD structure was through its
interaction with human Pin1, a unique prolyl isomerase
that catalyzes cis/trans isomerization of specific phos.Ser/
Thr-Pro motifs in signaling proteins (13 16). Identifica-
tion and characterization of this novel peptidyl-prolyl cis/
trans isomerase (PPIase), Pin1, led to discovery of a novel
postphosphorylation regulatory mechanism, in which
regulation is achieved by conformational changes of a
phosphorylated Ser/Thr-Pro peptide bond upon proline
isomerization (Fig. 2). This change in the configuration
of the polypeptide has a profound effect on Pin1 targets
and therefore modulates various signaling pathways
at both transcriptional and posttranslational levels.
Specifically, activity of prolyl-isomerization of Pin1 can
interconvert the cis/trans conformation of the phos.Ser/
Thr-Pro motif of target proteins and make them better
or worse substrates for conformation-specific signaling
kinases (such as cyclin-dependent protein kinase, glyco-
gen synthetase kinase 3 b, and mitogen-activated protein
kinase) and phosphatases (such as PP2A and Cdc25).
Recent studies also provide substantial evidence implicat-
ing Pin1 in progression of malignant tumor cells (17) and
development of Alzheimer’s disease (18). High affinity
inhibitory unnatural peptides have been developed as a
good template for chemical compounds targeting Pin1
for antineoplastic effects (19).
Compelling data have implicated human Pin1 as a key
modulator in the transcription mechanism. The yeast
homologue of Pin1, Ess1, interacts physiologically and
genetically with the CTD (20). Furthermore, hyperpho-
sphorylated RNA polymerase II appears to be the
dominant binding target in yeast extracts (21). Consider-
ing the high local concentration of the phos.Ser/Thr-Pro
motif in the hyperphosphorylated CTD, it is plausible
that the CTD is the major substrate of Pin1 in vivo. The
binding of a single CTD repeat that is phosphorylated at
Ser5 was reported to be 30 mM (22). Presumably, the CTD
tail containing 26 52 such repeats localizes a substantial
amount of Pin1.
Pin1 is a 163 amino acid polypeptide that can be
divided into two domains based on topology and
function, a C-terminal PPIase domain and an N-terminal
WW domain. Structure of the WW domain reveals three
antiparallel b-strands forming a shallow interface with
the PPIase domain for substrate peptide binding (23, 24).
Table 1. Summary of CTD interacting proteins/domains
Species Protein Method Preference PDB code References
Homo sapiens Pin1 X-ray Phos.Ser5 CTD 1f8a (22)
Saccharomyces cerevisiae Pcf11 CID X-ray Unphosphorylated CTD;
phos.Ser2 CTD
1sza (39)
Saccharomyces cerevisiae Nrd CID X-ray Phos.Ser5 CTD 3clj (43)
Homo sapiens SCAF8 CID X-ray Phos.Ser2 CTD 3d9i (46)
Homo sapiens Scp1 X-ray Phos.Ser5 CTD 2ght (65)
Schizosaccharomyces pombe Fcp1 X-ray Phos.Ser2 CTD 3ef0 (59)
Candida albicans Cgt1 X-ray Phos.Ser5 CTD 1p16 (67)
Homo sapiens Set2 SRI NMR Phos.Ser2 CTD 2a7o (77)
Saccharomyces cerevisiae Set2 SRI NMR Phos.Ser2 CTD 2c5z (78)
Homo sapiens CA150 FF NMR ?
a 2kis (82)
Saccharomyces cerevisiae Prp40 FF NMR ? 2b7e (81)
aNot determined.
Fig. 2. Cis and trans conversion of proline in a phos.Ser-Pro
motif. One mechanism of CTD phosphorylation is the
conversion of proline isomerization states.
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proline-containing sequences but it was not clear until
recently that WW domains join a group of modules that
bind to protein ligands in a phosphorylation-dependent
manner (25, 26); these domains include SH2, PTB, 14-3-
3, WD40, FHA, and FF domains. The modular nature of
WW domain interactions leads to a classification into
four distinct groups based on binding specificity (27).
Group I WW domains, such as dystrophin and the Yes-
associated protein YAP65, recognize ‘PpxY’ motifs (28).
Group II, such as FE65 and forming binding proteins
(FBPs), bind the ‘PPLP’ motif (29). A subset of FBPs
interacts with ‘PGM’ motifs (30). Group III WW
domains select polyproline motifs flanked by arginine
or lysine (31, 32). Group IV WW domain, including
human Pin1 and Nedd4, specifically recognize a phos.Ser/
Thr-Pro motif (22, 26, 33).
The molecular detail of recognition of the CTD by
Pin1 was elucidated by a structure of human Pin1 in
complex with one doubly phosphorylated CTD repeat
(22) (Fig. 3A). So far, this is the only structure available
for a full-length Pin1 binding to its target at the
recognition module WW domain. The structure is con-
sistent with thermodynamic data, which the phosphory-
lated Ser5 in the CTD repeat is the major binding element
in recognition. Loop 1 of the WW domain has been
shown to be highly flexible in apo Pin1 (34) but this loop
is essential for specificity recognition (35). In the complex
structure, this loop warps toward the substrate peptide to
ensure binding and results in an exaggerated twist in the
triple-stranded b-sheet (22) (Fig. 3A). This twist is
coupled to a contraction of the WW domain ligand
binding surface formed between the WW and PPIase
domains. The two essential elements for peptide recogni-
tion include binding of phosphate by loop 1 residues and
hydrophobic stacking of proline by Tyr23 and Trp34 (22).
The binding of Pin1 to the CTD can modulate the
regulatory effect of other CTD-binding proteins. In
vitro experiments showed that Pin1 can influence the
phosphorylation status of the CTD by inhibiting
the transcription factor IIF-interacting CTD phosphatase
1 (Fcp1) and stimulating CTD phosphorylation by cdc2/
cyclinB (36, 37). The Rsp5, a ubiquitin ligase that binds
to the CTD, also functions to oppose Pin1 effects on
RNA polymerase II (38). The biological and structural
results of Pin1 effects on RNA polymerase II function
support a model that Pin1 works in a processive manner
on the CTD with the WW domain acting as a binding
element restricting movement to an efficient one-
dimensional walk and with the PPIase acting much like
a reading head to processively isomerize the peptide
bonds. The binding of Pin1 prolongs the phosphorylated
state of the CTD by suppressing dephosphorylation,
thereby enhancing the regulatory effect of CTD binding
proteins.
CTD-interacting domain (CID) domain and the
C-terminal domain (CTD)
Recognition of the phosphorylated CTD by Pin1 is
mediated by its WW domain, a modular domain of
around 40 residues that is essential for recognition of
proline-rich motifs by the PPIase domain. The Pin1 WW
domain also recognizes other substrates in addition to the
CTD. A more specific recognition domain for the CTD is
the CTD-interacting domain (CID) identified in multiple
RNA processing and termination factors in eukaryotes
(39, 40) (Fig. 4).
In yeast, the effective termination of transcription
relies on the recruitment of cleavage factors by Pcf11.
The Pcf11 is a yeast protein of 70 kD with a CID domain
directly targeted to the CTD of RNA polymerase II,
which gives us the first glance of how a CID recognizes
Fig. 3. Ribbon representation of four CTD recognition
modules. (A) WW domain of Pin1 in complex with a short
CTD peptide (1f8a); (B) CID domain of Pcf11 in complex
with a short CTD peptide (1sza); (C) SRI domain of Set2
(2a7o); and (D) FF domain of CA150 (2kis).
Fig. 4. Superimposition of CID domains from Pcf11 (light
blue, 1sza), Nrd1 (light pink, 3clj), and SCAF8 (white, 3d9i).
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domain of Pcf11 can bind to both unphosphorylated
or phos.Ser2 CTD in biophysical binding assays (39).
Consistent with the biochemical data for such prefer-
ences, the co-crystal structure of the Pcf11 CID and a
CTD peptide shows no direct interaction between the
phosphate group of phos.Ser2 and Pcf11, indicating no
prerequirement of phosphorylation of the CTD for
protein binding (39) (Fig. 3B). The CID domain, as an
eight-helical bundle, recognizes a span of two heptad
repeats in the CTD with a conserved groove, whereas the
phosphate group of phos.Ser2 actually forms an intra-
molecular hydrogen bond with Thr4 of the CTD and
stabilizes the sharp b-turn formed by CTD, presenting
the side chain to the binding groove (Fig. 3B). Hydrogen
bondings between the CID domain and the CTD peptide
are distributed between the CID side chain and the main
chain amide and carbonyl group of the CTD peptide.
Importantly, hydrophobic interaction by Tyr1 of the CTD
to CID might contribute greatly for the specificity for
phos.Ser2 over phos.Ser5. Meinhart and Cramer (39)
conclude that Ser2 phosphorylation stabilizes the CTD
b-spiral that is incorporated into the transcription com-
plex. Ser5 phosphorylation would unwind the spiral
resulting in an extended region that binds the capping
enzyme. Overall, the binding of Pcf11 is not particularly
strong but is consistent with its dynamic role involved in
dismantling the elongation complex (41, 42).
Another CID containing protein Nrd1 is an essential
player in the termination pathway for RNA polymerase
II-mediated transcription for snoRNA, snRNA as well as
cryptic unstable transcripts (CUT). The complex of
Nrd1-Nab3-Sen1 is recruited to the transcription ma-
chinery through the CTD by the CID domain of Nrd1
of the complex. The CID domain derived from Nrd1
(Fig. 4) has a very similar overall fold and a strong
conservation of residues involved in CTD peptide binding
with Pcf11, but Nrd1 shows a different specificity profile
in which a much stronger preference for phos.Ser5 over
phos.Ser2 in the CTD sequence is detected for the CID
from Nrd1 by in vitro binding assays (43). Using yeast-
two hybrid and fluorescence anisotropy, Vasiljeva showed
a tenfold improvement in binding affinity for singly
phosphorylated CTD double repeats at Ser5 over Ser2
(Kd 40 mM for phos.Ser5 vs. 390 mM for phos.Ser2) and
a slight improvement when the peptide is doubly phos-
phorylated (Kd 16 mM upon double phosphorylation
for both Ser2 and Ser5 sites). Specificity for phos.Ser5 on
the protein is essential to understand how different
termination pathways are selected. A potential different
phosphate binding site was proposed but more insightful
information about specificity will only be available with a
structure of the Nrd1 CID complexed with the CTD
peptide. Since the Nrd1-dependent termination pathway
is usually associated with much shorter transcripts (a few
hundred base-pairs), upon which point dephosphoryla-
tion of Ser5 is not complete, a logical hypothesis is that
phosphorylation at Ser5 favors the selection of Nrd1
complex as a termination pathway in yeast. Indeed,
Gudipati et al. (44) showed that reducing phosphoryla-
tion of Ser5 using a mutant of kin28, a CTD Ser5 kinase,
will hamper Nrd-dependent termination. The selectivity
for phos.Ser5 over phos.Ser2 might be the determining
factor for the selection of termination pathways. A
functional model for how the phosphorylation pattern
of the CTD determines the transcriptional pathways
suggests that termination by the Nrd1-Nab3-Sen1 com-
plex is enforced when the CTD is still highly phosphory-
lated at Ser5 (45). The structure of a complex of the CID
of Nrd1 with the CTD domain will help provide a
molecular explanation of transcription termination.
Another CID containing protein human SCAF8 was
crystallized with different phosphorylated forms of CTD
peptides (Fig. 4), providing more clues about how
registration of a phosphate group on the CTD is encoded
in target recognition for CID domains (46). The SCAF8
is implicated in splicing with a preference of phos.Ser2,
similar to mRNA 3?-processing factor Pcf11. Indeed, a
similar conformation of beta-turn adapted by the CTD is
observed in SCAF8 upon peptide binding but with one
major distinction: phos.Ser2 is directly recognized by a
basic residue, Arg112, through salt bridge interaction
(46). At a similar position in Pcf11, a methionine residue
was placed with no direct interaction with the CTD
peptide. The replacement of methionine by arginine in
SCAF8 distinguishes the phos.Ser2 CTD from the unpho-
sphorylated form and might explain a tighter interaction
for SCAF8 toward phosphoryl-peptide (68 mM). In the
study of Becker et al. (46), an issue was raised whether
phosphorylated Ser7 contributes to recognition by the
CID domain of SCAF8. Binding affinity measured by
fluorescence anisotropy showed no advantage with addi-
tional Ser7 phosphorylation (68 mM for phos.Ser2 and
90 mM for doubly phosphorylated Ser2 and Ser7).
Consistent with the binding interaction measurement,
the structure of the complex with the SCAF8 CID
presents no interaction between the phosphate group of
Ser7 with the protein.
Small C-terminal domain phosphatases (Scp)/
Fcp phosphatases and the C-terminal domain
(CTD)
A wide range of enzymes participate in dynamic mod-
ifications of the CTD, including kinases and phospha-
tases responsible for addition and removal of phosphates.
The CTD is principally phosphorylated by cyclin-
dependent kinases (CDKs) with their associated cyclins.
Specifically, Ser5 phosphorylation is mainly catalyzed by
Cdk7/cyclin H subunits of TFIIH (47 49); Ser2 phos-
phorylation is mainly catalyzed by P-TEFb, which
The C-terminal domain of eukaryotic RNA polymerase II
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is suggested that Cdk9 also makes a contribution to Ser5
phosphorylation and the relative contribution of TFIIH-
associated Cdk7 varies between different genes based on
experimental observations (52). Moreover, the CTD can
also be phosphorylated at both Ser2 and Ser5 by Cdk8
as part of the mediator complex, and preferentially
phosphorylated at Ser5 by MAPK2/ERK2 (53). Recently,
TFIIH-associated Cdk7 kinase has also been shown to
phosphorylate Ser7 in vivo (52, 54). Even though struc-
tural information has been obtained for Cdk7 (55) and
Cdk9/cycln T (56), how they recognize the CTD peptide
and label the phosphorylation mark on CTD is still
elusive. It is assumed that specificity is achieved by other
associated proteins in the multiprotein complexes they
are involved (Cdk7 in TFIIH, Cdk8 in mediator, and
Cdk9 in P-TEFb).
Dephosphorylation is essential for recycling RNA
polymerase II, because after each round of transcription,
the CTD has to be dephosphorylated in order to actively
restart a new round of transcription. In humans, Fcp1,
which is required for general transcription and cell
viability, was the first discovered CTD-specific phospha-
tase with a catalytic preference for phos.Ser2. The Fcp1 is
conserved among eukaryotes and was shown to be
essential for cell survival in budding and fission yeast
(57, 58). The conserved region of Fcp1 is composed of
two domains: an N-terminal FCP homology (FCPH)
domain with phosphatase activity and a C-terminal
breast cancer protein related C-terminal (BRCT) domain
(59) (Fig. 5).
Recently, a family of small CTD phosphatases (Scps)
with activities preferential for phos.Ser5 was identified
(60, 61). This family includes three highly similar proteins
designated Scp1, Scp2, and Scp3. The Scps also contain
the FCPH catalytic domain that includes the DXDX(T/
V) motif, the signature of a superfamily of phospho-
transferases and phosphohydrolases called the haloacid
dehalogenase (HAD) superfamily (62). Therefore, Fcp/
Scp family members are classified as HAD superfamily
enzymes. Interestingly, outside the signature motif, Scps
share very little sequence similarity with the other
enzymes in the HAD superfamily (63). In humans, Scp1
has more than 20% sequence identity to Fcp1 in the
FCPH domain but lacks the C-terminal BRCT domain
that exists in Fcp1. Moreover, Scp2 and Scp3, which also
lack the BRCT domain, share more than 90% similarity
with Scp1 in the FCPH domain (60) (Fig. 5).
The apo structure of Scp1 solved by Kamenski et al.
(64) showed a central parallel b sheet flanked by two a
helices, a two-stranded b sheet, and a short 310 helix. The
conserved DXDX(T/V) signature motif lines part of a
central crevice, which forms the active site and coordi-
nates the Mg
2  ion that is essential to Scp1 phosphatase
activity. The first aspartate in the signature motif is
involved in Mg
2 -assisted phosphoryl transfer and acts
as the phosphoryl acceptor. Mutation of this residue
(Asp96 in Scp1) to alanine or asparagine abolished the
activity of Scp1. The second aspartate (Asp98 in Scp1)
also contributes to metal ion-binding and could possibly
function as a general acid/base (64). The proposed
phosphoryl transfer mechanism for the Scp/Fcp family
involves a phosphoryl-aspartate intermediate. Existence
of this phosphoryl-enzyme intermediate was confirmed in
a recent structural and functional study when we
successfully trapped the phosphoryl-aspartate intermedi-
ate in the crystal structure of an Scp1D206A mutant
soaked with para-nitrophenyl phosphate (pNPP) (63).
The steady-state kinetic analysis of a variety of Scp1
mutants revealed the importance of Asp206 in Mg
2 
coordination mediated by a water molecule. Moreover,
snapshots of the phosphoryl transfer reaction at each
stage of Scp1-mediated catalysis were also captured in
this study.
Fig. 5. Surface representation of Scp1 and Fcp1 FCPH domains. (A) Scp1 in complex with a short CTD peptide (2ght). The
zoom-in picture shows the Pro3 binds to the hydrophobic pocket with the aromatic residues shown in stick. (B) Fcp1 FCPH
domain (3ef0). In both structures, the active site signature motif is colored with pale green, and the insertion domain is colored
with light pink. Notably, the additional helical domain (light cyan) covers the ‘insertion domain’ in Fcp1 and makes it much less
accessible for substrates.
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over phos.Ser2 as a substrate by Scp1, the complex
structure of a dominant negative form of human Scp1
(Scp1D96N) bound with Ser2/Ser5-phosphorylated CTD
peptide was obtained by crystal soaking (65). The defined
complex structure revealed a unique binding mode of the
peptide in which Ser2Pro3Thr4(phos.Ser5) forms a b-turn.
The phos.Ser5 binds to the active site groove through
Mg
2  coordination. The Pro3 is recognized by an
aromatic-rich hydrophobic pocket near the active site
that further confers substrate specificity (65). Notably,
Scp1 shows remarkable specificity toward the trans
peptide-bond configuration of the two prolines in the
CTD repeat, which can adopt both cis and trans
configurations. Such configuration switching is known
to modulate the structure of the CTD and its accessibility
to kinases or phosphatases (21, 22). An insertion domain
formed by a three-stranded b sheet directly follows the
signature motif (Fig. 5). This insertion domain is unique
to Fcp1/Scp1 family phosphatases and may assist in
substrate recognition. Consistent with the known speci-
ficity of Scp1 toward phos.Ser5 instead of phos.Ser2,i n
the complex structure the phos.Ser2 flips out of the active
site, making no direct interaction with the protein.
Even though Scp and Fcp share similar phosphatase
active sites, their strategy for substrate recognition might
be different, as suggested by the recent crystal structure
of apo Schizosaccharomyces pombe Fcp1 (SpFcp1) (59)
(Fig. 5). The minimal effective CTD substrate for SpFcp1
is a single heptad CTD peptide: Ser5Pro6Ser7Tyr1(phos.-
Ser2)Pro3Thr4, among which the Tyr1 and Pro3 flanking
the phos.Ser2 are critical determinants of Fcp1 activity
(66). The SpFcp1 structure revealed that it is a Y-shaped
protein composed of three structural domains (59). The
stem of the Y is the FCPH domain that contains a
globular catalytic phosphatase core similar to that of
Scp1. One major difference is that the three-stranded
b sheet in Scp1 (insertion domain) is accessible for
substrate recognition, whereas in Fcp1 it is buried by a
helical insertion domain, suggesting a different binding
interface between Fcp and the CTD with phos.Ser2
(Fig. 5).
mRNA capping enzyme Cgt1 and the C-terminal
domain (CTD)
Even though 26 52 heptad repeats exist in the CTD
primary sequence, recognition of the CTD by proteins in
all the complex structures discussed above only show a
spanning of one or two repeats. This is understandable
since a balance between a favorable interaction of the
CTD with its binding partners versus the entropy cost for
binding a disordered peptide needs to be achieved. This
leads to the proposed mechanism that a double repeat of
the CTD sequence is the functional unit for transcription.
To explore if such rule is consistent with the mRNA
capping enzyme Cgt1, four heptad repeats each with their
Ser5 phosphorylated were used in a cocrystallization
experiment (67). Interestingly, a long span of CTD
peptide consisting of 17 amino acids was modeled in
the density of one of the two monomers with an extensive
buried surface of 1,600 A ˚ 2 (67). Three of the four
phosphorylated Ser5 residues were visible in this structure
with both the first and third phosphate group recognized
by positively charged patches on the Cgt1 surface.
Consistent with a previous study of Cgt1, the Tyr1
position in the CTD sequence is essential for recognition
by the protein (68). On the other hand, a single mutation
of the Cgt protein for the recognition interface did not
show obvious deleterious effects during yeast mutation
screening (67), possibly due to the extended binding
surface without one interaction dominating binding.
Since the other monomer in the asymmetric unit shows
a much smaller interface, it suggests that multiple
phosphorylation sites are not a prerequisite for ligand
binding. Further affinity measurements with a different
length and registration of the phos.Ser5 would elucidate
whether interaction with multiple repeats of the CTD is
essential for the effective binding by Cgt1.
Nuclear magnetic resonance (NMR) structure
of Set2
The identification of the histone methyltransferase Set2 as
a novel CTD binding partner bridges the CTD code to the
histone code by implicating the regulatory effect of the
CTD on histone modification and epigenetic control (69,
70) (Fig. 3C). In eukaryotes, large genomes are efficiently
organized into nucleosomes that are fundamental repeat
units of chromatin. The nucleosome is composed of a
histone octamer consisting of two copies of each of the
core histones H2A, H2B, H3, and H4, around which 147
bp of DNA is wrapped. Such a structure is not only a
strategy to compress large genomic DNA, but also
provides a potential solution for tight regulation of
DNA replication, repair, and transcription. During tran-
scription, for example, the binding sites for a variety of
transcription factors can be occluded by histones, leading
to transcriptional silencing (71). Access to specific loci on
the nucleosomal DNA is dynamically regulated by many
factors including chromatin modifiers and chromatin
remodelers. Histones can be covalently modified by
chromatin modifiers at particular loci, most of which
are concentrated in the relatively unstructured N-terminal
tails of histones. These modifications include acetylation,
methylation, phosphorylation, ubiquitination, and su-
moylation (72). The histone code, which is defined by
covalent modifications, represents a fundamental regula-
tory mechanism of gene expression and repression (73).
Furthermore, the histone code can be interpreted by
different modules in a modification-dependent manner to
decide whether a gene is to be transcribed.
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Rpb1 interacting (SRI) domain, mediates the recognition
and interaction with the phosphoryl CTD (Fig. 3C). Lys4
of histone 3 is methylated by the proteins of the Set1
family, while Lys36 is methylated by proteins of the Set2
family (69). Both Set1 and Set2 associate with the CTD
but at different stages of transcription: Set1 binds to
phosphorylated CTD enriched with Ser5 at the promoter
region through the mediation of the Paf complex (74, 75);
whereas the recognition of the CTD by Set2 relies on the
phosphorylation of Ser2 in heptad repeats (76). The SRI
domains from both human (77) and yeast (78) Set2 were
determined by NMR and the binding interface mapped
by phosphoryl-peptide titration. The study of affinity
with different length and phosphorylation registration
showed that single repeats are not sufficient for SRI
recognition and a strong preference for doubly phos-
phorylated peptide was observed. Five residues were
identified as essential for the effective association between
Set2 SRI and the CTD using NMRand mutagenesis (74).
One can assume the positively charged residues, Lys54,
Arg58, and His62 of the Set2 SRI, are involved in
phosphate binding whereas Val31 and Phe53 are impor-
tant for hydrophobic interaction with the side chain
residues of the CTD, possibly tyrosine or proline.
In addition, the FF domain is a protein-protein
interaction module existing in several CTD interaction
proteins such as human transcription factor CA150 (79)
and splicing factor Prp40 (80). Like the SRI domain, the
FF domain exhibits a structure of three-helical bundle
(Fig. 3D). The FF domains usually are arranged as
tandem arrays in proteins and such architecture might
account for interaction with the CTD with each module
contributing very weakly to binding. Identification of the
specificity of phosphorylation states of the CTD recog-
nized by FF domains has been challenging due to the
weak binding. In vitro binding assays and NMR titration
experiments did not detect interaction with a CTD
peptide with the FF domain arrays derived from Prp40
(81) or CA150 (82). A binding constant of 50 mM was
reported for the mammalian homologue of Prp40,
FBP11, using isothermal titration calorimetry (83) but
detailed information about the interaction between
molecules is yet to be elucidated.
Concluding remarks
Recognition of the phosphorylation states of the CTD is
essential for mediation of the expression of genetic
information. Proteins that are highly selective toward
specific phosphorylated forms of the CTD decipher the
‘CTD code’ and synchronize the transcriptional events
accordingly. Communication of the CTD and histone
codes provides an exquisite regulatory network for the
precise control of transcription at multiple levels. Some
CTD interacting proteins function as global transcrip-
tional regulators non-discriminatingly. The inactivation
of such molecules will lead to the shutdown of transcrip-
tion machinery and eventually, cell death. For example,
the deletion of the CTD Ser2 phosphatase Fcp1 is lethal
for yeast due to the abolishment of RNA polymerase II
recycling (58, 84). Similar effects on yeast are observed
when the CTD Ser5 phosphatase Ssu72 is eliminated (85).
On the other hand, evidence has indicated that
CTD-interacting proteins can control gene expression at
an epigenetic level and regulate expression of specific
genes based on timing and the developmental needs.
Human Scps are only found in higher eukaryotes and
their expression is limited to neuronal stem cells or non-
neural tissues. Consistent with their unique expression
profile, Scps are identified as a component of the
neuronal chromatin remodeling complex, REST (61).
The inactivation of Scp activity leads to the inappropriate
differentiation of neuronal stem cells (61). Another
example of epigenetic regulation of a CTD-interacting
protein is the Cdk8/cyclin C pair, which has been linked
to transcriptional repression (48). Histone methyltrans-
ferases Set1 (75) and Set2 (74) can identify the different
phosphorylation stages of CTD. The phosphorylation of
Ser7 of CTD itself also occurs in a gene-specific fashion
(12). The apparent simple primary sequence of CTD
integrates genetic and epigenetic information and plays a
pivotal role in transcriptional activation or repression.
Understanding how such coding is deciphered at the
molecular level is essential to the interpretation of the
central role of RNA polymerase II and its regulatory
domains. The application of CTD code provides a unique
opportunity to engineer the transcriptional process in an
epigenetic level in tissue-specificity manner.
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